An Open-label Phase 2 Study to Assess the Effect of C5aR Antagonist Therapy by CCX168 Oral Administration on ex Vivo Thrombus Formation and Disease Activity in ESRD Patients With Atypical Hemolytic Uremic Syndrome
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Ex vivo thrombogenesis.
研究概览
简要总结
This study evaluates the effect of CCX168, a C5aR Antagonist, Oral Administration on Ex Vivo Thrombus Formation and Disease Activity in ten patients with diagnosis of Atypical Hemolytic Uremic Syndrome with or without genetic abnormalities in the complement system or thrombomodulin, on stable chronic extracorporeal or peritoneal dialysis therapy since at least 6 months.
详细描述
Inherited defects that determine uncontrolled activation of the alternative complement pathway have been well documented in atypical Hemolytic Uremic Syndrome (aHUS) patients. Research in recent years has identified more than 120 different mutations, accounting for around 40%-60% of cases, in the genes encoding complement factor H (CFH), membrane cofactor protein (MCP), complement factor I (CFI), C3, complement factor B (CFB), and thrombomodulin (THBD). A therapeutic approach could be the administration of molecules that pharmacologically target complement activation, which is the primary common pathogenic mechanism in all genetic forms of aHUS. Eculizumab has been successfully used as prophylaxis of aHUS recurrences in subjects with plasma dependent or plasma resistant disease or in renal transplant recipients at high risk of recurrence due to CFH, CFI, or C3 complement gene mutations. However the drug must be administered chronically and drug spacing or discontinuance was associated with disease recurrence in the graft. The C5aR receptor antagonist CCX168 could present an appealing alternative to eculizumab for post-transplant prophylaxis of aHUS recurrences since it is orally administrable with lower cost of goods. In addition, CCX168 is theoretically associated with lower risk of infections than eculizumab since the former does not target C5b and leaves the terminal complement pathway intact.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age >18 years;
- •Diagnosis of aHUS with or without identified genetic abnormalities in the complement system or thrombomodulin;
- •Stable chronic extracorporeal or peritoneal dialysis therapy since at least 6 months;
- •Written informed consent.
排除标准
- •Women of childbearing potential or women who are breastfeeding;
- •Shiga toxin-associated HUS or secondary forms of thrombotic microangiopathy;
- •ADAMTS13 activity <10 % or circulating anti ADAMTS13 autoantibodies consistent with the diagnosis of thrombotic thrombocytopenic purpura;
- •Need for specific intervention with plasma therapy and/or complement inhibitors as deemed clinically appropriate;
- •Plasma therapy or treatment with complement inhibitors or antiplatelet and antithrombotic agents over the last two weeks;
- •Liver function impairment (serum liver enzymes or bilirubin levels >3 x upper limit of normal);
- •Neutrophil count < 2000/μL or lymphocyte count < 1000/μL;
- •Infection requiring antibiotic treatment within the previous 4 weeks prior to screening;
- •Participated in any clinical study of an investigational product within 30 days prior to screening or within 5 half-lives after taking the last dose;
- •History or presence of any medical condition or disease which, in the opinion of the Investigator may place the subject at unacceptable risk for study participation;
- •Inability to understand the potential risks and benefits of the study;
- •Legal incapacity.
研究组 & 干预措施
CCX168
Study medication will be administered as hard gelatin capsules containing 10 mg CCX168. Patients will take 30 mg CCX168, given as 3 x 10 mg capsule, twice daily for 15 days.
干预措施: CCX168 (Drug)
结局指标
主要结局
Ex vivo thrombogenesis.
时间窗: Changes from baseline at day 2,14 (during CCX168 treatment), 16 and 21 (after treatment withdrawal).
次要结局
- Complement Factor H.(Changes from baseline at day 2,14 (during CCX168 treatment), 16 and 21 (after treatment withdrawal).)
- Complement component 5 serum levels.(Changes from baseline at day 2,14 (during CCX168 treatment), 16 and 21 (after treatment withdrawal).)
- Complement component 5a.(Changes from baseline at day 2,14 (during CCX168 treatment), 16 and 21 (after treatment withdrawal).)
- Fibrin split products..(Changes from baseline at day 2,14 (during CCX168 treatment), 16 and 21 (after treatment withdrawal).)
- Characterization of CCX168 pharmacokinetic profile after oral administration by determining by maximum plasma concentration, time of maximum plasma concentration and area under the plasma concentration-time curve from time 0 to hour 6(Changes from Baseline at 4,9,11 and 15 day.)
- Complement component 3 serum levels.(Changes from baseline at day 2,14 (during CCX168 treatment), 16 and 21 (after treatment withdrawal).)
- Complement component 4 serum levels.(Changes from baseline at day 2,14 (during CCX168 treatment), 16 and 21 (after treatment withdrawal).)
- Soluble thrombomodulin.(Changes from baseline at day 2,14 (during CCX168 treatment), 16 and 21 (after treatment withdrawal).)
- Ex vivo C5b-9 deposition on microvascular endothelial cells(At baseline.)
- Changes in pre-dialysis and intradialytic blood pressure.(The participants will be followed for the duration of the study up to 21 days.)
- Changes in heart rate.(The participants will be followed for the duration of the study up to 21 days.)
- Safety and tolerability parameters including serious and non serious events(The participants will be followed for the duration of the study up to 21 days.)
- Patient health-related quality of life as measured by administration of EQ-5D-5L questionnaire.(Changes from baseline at 14 and 21 day.)